anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
See MIXING GUIDELINES AND LIMITATIONS section for information regarding mixing this fat emulsion with other parenteral fluids. 

Intralipid 20% can be infused into the same central or peripheral vein as carbohydrate/amino acids solutions by means of a Y-connector near the infusion site. This allows for mixing of the emulsion immediately before entering the vein or for alternation of each parenteral fluid. If infusion pumps are used, flow rates of each parenteral fluid should be controlled with a separate pump. Fat emulsion may also be infused through a separate peripheral site. Use a 1.2-micron filter with Intralipid 20%. Filters of less than 1.2-micron pore size must not be used. Conventional administration sets and TPN pooling bags contain polyvinyl chloride (PVC) components that have DEHP (di(2-ethylhexyl) phthalate) as a plasticizer. Fat‑containing fluids such as Intralipid 20% extract DEHP from 

these PVC components and it may be advisable to consider infusion of Intralipid 20% through a non-DEHP administration set. Do not use any bag in which there appears to be an oiling out on the surface of the emulsion. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
AIM: Colorectal cancer rates are increasing in older populations, who often have comorbidities and face higher surgical risks and mortality rates. Therefore, surgical outcomes, such as 5-year mortality rates, may not be appropriate, necessitating a focus on postoperative quality of life. However, determining optimal postoperative outcome measures for older colorectal cancer patients poses a challenge. This scoping review aimed to explore currently available data describing postoperative outcomes used to assess older patients undergoing elective colorectal cancer surgery.
METHOD: We conducted a comprehensive literature search of major electronic databases from inception to March 2023. Studies exploring frail or older individuals with colorectal cancer undergoing elective surgical procedures, and which reported postoperative outcomes, were included. Outcomes were categorized as surgery-specific versus person-centred and summarized using narrative synthesis. The type and rate of surgery-specific outcomes were tabulated.
RESULTS: Of 1366 identified citations, 16 studies focused on person-centred outcomes and 66 reported exclusively on surgery-specific outcomes. Nine 'person-centred outcome' studies reported discharge destination, primarily home discharge. Postoperative delirium ranged from 8.2% to 18.1% in six studies. Four studies explored geriatric syndromes, three analysed activities of daily living, and three studies reported significant quality of life improvement. The 66 'surgery-specific outcome' studies assessed mortality (N = 61); length of stay (N = 40); postoperative complications (N = 47); readmission (N = 18); reoperation (N = 16); and survival (N = 42).
CONCLUSION: Person-centred outcomes are underreported, but crucial for guiding patient management. Older patients require adequate information about their postoperative recovery period to enhance wellbeing. Future research must address this gap to improve care for older people undergoing elective colorectal cancer surgery.
Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
ABSTRACT OF THE DISCLOSURE            A system for testing microbiological specimens and reporting the results thereof. The system comprises at least one workstation which is coupled to a patient information database and a microbiology database. The workstation has data entry means which include a scanner. The specimen is assigned a machine readable identifier. The machine readable identifier is also referenced to data in the patient information database. The workstation uses the scanner to read the identifier assigned to the specimen and retrieve patient information for the specimen. The workstation produces a screen display which comprises the retrieved patient information in addition to interactive fields for performing the microbiological testing of the specimen. The interactive fields include a field for inserting the type of medium used, a field for inserting the observation concerning the specimen, and a field for inserting a description relating to the specimen. Once the testing and recording of results has been completed, the workstation produces a report in electronic form which can be transmitted to remote location.
"Pigmentibacter ruber" was first reported in 2021, a novel bacterium of the family Silvanigrellaceae, isolated from human blood of the patient with aspiration pneumonia after the drowning accident in Republic of China. However, until now, there is only one report describing "P. ruber" infection, and no case of isolation from natural environment has been reported so far. Thus, the infectivity and pathogenicity of "Pigmentibacter" spp. has not been clearly understood. In this report, we described the fatal case of "Pigmentibacter" bacteremia subsequently occurred after aspiration pneumonia probably due to accidental ingestion of irrigation water in the elderly patient. Despite administration of broad-spectrum antibiotic, the patient dramatically deteriorated and eventually deceased. Whole-genome sequencing showed the strain isolated from the patient was identified as "Pigmentibacter" sp. (designated as strain Takaoka) and antimicrobial sensitivity testing showed it displayed high minimum inhibitory concentrations against various antibiotics including β-lactam. Further studies are needed to clarify the clinical characteristics of "Pigmentibacter" and its relative's infections and their antimicrobial sensitivity; however, the present case supported the clinical characteristics of "Pigmentibacter" infection, which can lead to bacteremia following aspiration pneumonia caused by mis-swallowing contaminated water, and poor outcome potentially due to multidrug resistances.
Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
Cefdinir for oral suspension, USP is a white to off-white powder formulation that, when reconstituted as directed, contains either 125 mg cefdinir/5 mL or 250 mg cefdinir/5 mL. The reconstituted suspension has a white to off-white color and cherry flavor. The powder is available as follows:

250 mg/5 mL – in bottles of 100mL (NDC 68788-8655-1).

Store the unsuspended powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Once reconstituted, the oral suspension can be stored at controlled room temperature for 10 days.

Keep this and all medications out of the reach of children.
Histoplasmosis is a serious opportunistic infection in patients with AIDS. Amphotericin B has been used to treat the infection. Although the response to this treatment is generally good, up to 90 percent of AIDS patients who have taken amphotericin B to treat their histoplasmosis infection will have a relapse (that is, they will get the disease again) within 12 months following treatment. Ketoconazole has been used to prevent relapse, but available information suggests that up to 50 percent of AIDS patients relapse even with ketoconazole treatment. A more effective therapy to prevent recurrence is needed. Itraconazole has been used successfully to treat disseminated histoplasmosis in non-AIDS patients and it is hoped that it may be more effective in preventing histoplasmosis relapse.

AIDS patients who have been successfully treated with amphotericin B for an acute first episode of disseminated histoplasmosis are selected for treatment. They receive daily oral doses of itraconazole for a total of 52 weeks. Patients who do not experience significant toxicity related to the drug may continue to receive itraconazole until the last patient completes 52 weeks of itraconazole therapy or has the study drug discontinued prior to completing 52 weeks of therapy. AMENDED: Patients will be treated for a minimum of 52 weeks. Patients who complete the 52 weeks and remain on the study drug will continue to be followed. If itraconazole becomes licensed for histoplasmosis, study drug must be discontinued at the end of 52 weeks of therapy or at the time of licensure for patients who have received more than 52 weeks of therapy.
Two similar, randomized, double-blind, placebo-controlled, multi-center studies were conducted in a total of 562 adult patients in remission from ulcerative colitis. The study populations had a mean age of 46 years (11% age 65 years or older), were 53% female, and were primarily white (92%).

Ulcerative colitis disease activity was assessed using a modified Sutherland Disease Activity Index (DAI), which is a sum of four subscores based on stool frequency, rectal bleeding, mucosal appearance on endoscopy, and physician’s rating of disease activity. Each subscore can range from 0 to 3, for a total possible DAI score of 12.

At baseline, approximately 80% of patients had a total DAI score of 0 or 1.0. Patients were randomized 2:1 to receive either mesalamine extended-release capsules 1.5 g or placebo once daily in the morning for six months. Patients were assessed at baseline, 1 month, 3 months, and 6 months in the clinic, with endoscopy performed at baseline, at end of study, or if clinical symptoms developed. Relapse was defined as a rectal bleeding subscale score of 1 or more and a mucosal appearance subscale score of 2 or more using the DAI. The analysis of the intent-to-treat population was a comparison of the proportions of patients who remained relapse-free at the end of six months of treatment. For the table below (Table 3) all patients who prematurely withdrew from the study for any reason were counted as relapses.

In both studies, the proportion of patients who remained relapse-free at six months was greater for mesalamine extended-release capsules than for placebo.

Examination of gender subgroups did not identify difference in response to mesalamine extended-release capsules among these subgroups. There were too few elderly and too few African-American patients to adequately assess difference in effects in those populations.

The use of mesalamine extended-release capsules for treating ulcerative colitis beyond six months has not been evaluated in controlled clinical trials.
BACKGROUND: The prognostic significance of lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) remains controversial. Notably, there is evidence suggesting an association between tissue stiffness and the aggressiveness of the disease. We therefore aimed to explore the effect of tissue stiffness on LNM-related invasiveness in PTC patients.
METHOD: A total of 2492 PTC patients from 3 hospitals were divided into an LNM group and a non-LNM group based on their pathological results. The effects of interior lesion stiffness (E) and peri-cancerous tissue stiffness (Eshell) on the LNM-related recurrence rate and mortality in each patient with PTC subgroup were analyzed. The activation of cancer-associated fibroblasts (CAFs) and extracellular matrix component type 1 collagen (COL-I) in the lesion were compared and analyzed across different subgroups. The underlying biological basis of differences in each subgroup was identified using RNA sequencing (RNA-seq) data.
RESULTS: The Eshell value and Eshell/E in the LNM group were significantly higher than those in the non-LNM group of patients with PTC (Eshell: 72.72 ± 5.63 vs 66.05 ± 4.46; Eshell/E: 1.20 ± 1.72 vs 1.09 ± 1.10, P < .001). When Eshell/E > 1.412 and LNM were both present, the recurrence rate and mortality were significantly increased compared to those of group of patients with LNM (91.67% and 7.29%, respectively). The CAF activation and COL-I content in the Eshell/E+ group were significantly higher than those in the Eshell/E- group (all P < .001), and the RNA-seq results revealed significant extracellular matrix (ECM) remodeling in the LNM-Eshell/E+ group.
CONCLUSIONS: Stiff peri-cancerous tissue induced CAF activation, COL-I deposition, and ECM remodeling, resulting in a poor prognosis for PTC patients with LNM.
The invention discloses a pentanone thiophene compound, a preparation method thereof and application thereof in anti-inflammatory drugs. The inventors obtained compounds Ochratinols A and B ((. + -.) -1 and (. + -.) -2) by separating and purifying Aspergillus antarctica sp.SCSIO 05702 liquid fermentation extract. Through structural analysis, the compounds 1 and 2 are novel compounds, and the specific structure is shown as a formula (I). Through the anti-inflammatory activity evaluation of the compounds 1 and 2, the novel compound Ochratinol A (1) has remarkable inhibition effect on nitric oxide generated by a Lipopolysaccharide (LPS) induced mouse macrophage strain RAW264.7, simultaneously inhibits mRNA expression of proinflammatory factors such as IL-6, TNF-alpha and the like, has no cytotoxic activity on RAW264.7 cells at the same concentration, and can be used as a lead compound for developing anti-inflammatory drugs.
PURPOSE:The titled monomer, obtained by treating IgG derived from humans with an acid under specific conditions, and removing dimer and/or polymer of the IgG, and capable of intravenous injection. CONSTITUTION:IgG monomer, obtained by treating a 0.2-20wt/vol% solution of human IgG containing dimer and/or polymer thereof as an impurity with an acid at 3.7-4.3pH for 30min-20hr to dissociate the human IgG polymer into monomer thereof, and capable of intravenous injection. Preferably, 0.5-20wt/ vol% at least one stabilizer selected from inorganic salts, e.g. NaCl or KCl, saccharides, e.g. glucose, fructose or sorbitol, proteins, e.g. albumin or gelatin, and organic acid salts, e.g. oxalates or citrates, is added thereto to prevent the denaturation of IgG. The presence of the stabilizer intact after the production of the IgG is preferred from the viewpoint of storage stability of the IgG.
A substance having the property of inhibiting the growth of tissues is obtained from parathyroid glands by neutralizing an acid extract of the glands to a pH of 4,6 to 5,0, filtering off the insoluble matters precipitated and treating the filtrate to concentrate or purify the hormone therein.  The filtrate may be concentrated under reduced pressure the pH being readjusted if necessary to 4,5 to 5,0. The acid liquid may consist of water, an alcohol, e.g. ethyl alcohol, or a ketone, e.g. acetone, and an acid, e.g. sulphuric or hydrochloric acid.  The fat may be extracted by treatment of the glands with a fat solvent prior to or simultaneously with treatment with the acid liquid.  Examples: (1) Minced glands are shaken with a mixture of water, sulphuric acid, alcohol, and benzene; strained off and the benzene separated.  The acid alcoholic liquid is neutralized with caustic soda to pH 4,8.  Alcohol is added to precipitate sodium sulphate and the liquid after filtration is concentrated in vacuo, and the pH adjusted to 4,8.  (2) Glands are shaken with strong alcohol containing 5 per cent concentrated sulphuric acid, the liquid is neutralized till slightly acid to litmus, filtered, and concentrated by distillation and adjusted to pH=4,8, (3) Glands are treated on a boiling water bath with dilute sulphuric acid, the liquid is cooled and the fat separated and its pH adjusted to pH=9 by addition of sodium hydroxide, strained and centrifuged. The liquid is then neutralized with sulphuric acid to pH=4,8, allowed to stand in the cold and centrifuged.  The precipitate so obtained is dissolved in dilute alkali, the pH adjusted to pH=4,8, centrifuged and the filtrate added to that first obtained.  Alcohol is added to precipitate sodium sulphate and the filtrate concentrated.  (4) Glands are macerated with acetone, and the solid residue is dried, ground and treated with dilute sulphuric acid.  The solution obtained is treated in a similar manner to that of example 3.
FIELD: cosmetology, particularly, preparations for care of hands, face and body skin. SUBSTANCE: proposed cosmetic composition may be made in the form of face nutritious cream, face cream-mask, and protective cram for hands. For preparation of face nutritious cream used are extract of lucerne herb in amount of 0.5-1.5 mas.%, base, containing mink oil, distilled water and flavor. For preparation of face cream-mask and protective cream for hands used, as a base, are lanolin, vaseline, vegetable oil, distilled water and flavor, while extract of lucerne herb is used in amount of 3.0-7.0 and 8.0-12.0 mas.%, respectively. EFFECT: higher biological activity and improved biological and morphological skin properties. 3 cl, 3 ex
PROBLEM TO BE SOLVED: To obtain a drug preparation capable of efficiently holding a hydroxamic acid compound and releasing the compound at a sustained rate by using the hydroxamic acid compound together with a specific polymer degradable in vivo. SOLUTION: A hydroxamic acid compound is used in combination with a polymer having a free carboxyl group and degradable in vivo. At least one of the above components is used in the form of a metal salt. The metal salt is preferably selected from Ca, Mg, Al, Zn and Fe salts. The polymer degradable in vivo is preferably an α-hydroxycarboxylic acid polymer or a lactic acid- glycolic acid copolymer. The sustained release agent can be produced e.g. by dissolving or dispersing a hydroxamic acid compound and a polymer having a free carboxylic acid and degradable in vivo in an organic solvent using at least one of the hydroxamic acid compound and the polymer in the form of a metal salt, adding the solution or dispersion to an aqueous phase and drying in water. The sustained release agent is preferably used in the form of microcapsule and is most suitable for injection.
718,287. Inhalers; vaporizers. BRUCKBAUER, H., and GOTZ, G. Oct. 19, 1951 [Dec. 12, 1950; July 25, 1951], No. 24475/51. Classes 81(1) and 81(2) Apparatus for the cold evaporation of liquid inhaling substances comprises a casing provided with a porous absorbent wick, a fan being provided within the casing which draws air through an opening in the casing, causes if to flow over the wick, one end of which extends into a container for the liquid to be vaporized, and subsequently forces air out of the casing through another opening. A casing 20 is provided with a perforated bottom 21 through which air is drawn into the casing 20 by a propeller 24 driven by an electric motor 22. The air is driven through openings 33 to the interior of a tube 27 mounted in a cover 25 at the top of the casing 20. A round wick 28 within the tube 27 extends into inhalant liquid in a container 30 secured to the bottom of the tube 27. After passing over the wick 28, the air leaves the apparatus through holes 34 in a closure 26 mounted in the cover 25. The exit holes 34 may be omitted and a closure provided having a flexible tube attached by which vapour may be supplied to a patient. In another construction (Fig. 2) the casing comprises an upper part 51 open at the bottom and provided with a screw cap 53 for insertion into a lampholder. an electric motor 54 and a propeller 58, and a lower portion 52 open at the top and which serves as a container for inhalant liquid 73. An annular wick 79 is held against the wall of the lower portion 52 by a perforated ring 76 which is integral with a cover 77 for the liquid.. The bottom of the lower portion 52 has a central recess 71 by which it is mounted on a pin 69 depending from a bridge 66 secured across the open end of the upper portion 51. The cover 77 is also mounted on the pin 69. Air is drawn into the container through holes 56 in the upper portion 51 and is driven out through a space- 80 between the upper and lower portions 51, 52. The propeller 58 is formed from a sheet iron disc from which upwardly bent flaps 62 are formed.
OBJECTIVES: To evaluate the extent of hearing loss among pottery workers in Mexico exposed to lead.
DESIGN: The authors conducted a cross-sectional study including 315 adult pottery workers. Auditory function was evaluated by air conduction pure-tone audiometry (pure-tone average) and distortion-product otoacoustic emission (DPOAE) levels (amplitude and signal-to-noise ratio). Lead exposure was assessed with a single blood sample test and classified as low, medium, and high according to blood lead tertiles. Logistic regression models were calculated for the association between blood lead levels, pure-tone average, and DPOAE records.
RESULTS: Median (25th-75th) blood lead levels were 14 μg/dL (7.5-22.6 μg/dL). The audiometric pattern and DPOAE records were similar across blood lead levels groups in all frequencies, and no statistically significant differences were found. Adjusted logistic regression models showed no increase in the odds for hearing thresholds >25 dB (HL) and DPOAE absence associated with blood lead levels, and no dose-response pattern was observed ( p > 0.05).
CONCLUSIONS: Given the results from this cross-sectional study, no association was found between blood lead levels and hearing loss assessed with DPOAE. Future longitudinal work should consider chronic lead exposure estimates among underrepresented populations, which can potentially inform safer work practices to minimize the risk of ototoxicity.
QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
The recommended starting dose of XATMEP is 10 mg/m2 given one time weekly.

Dosages should be tailored to the individual patient and adjusted gradually to achieve an optimal response. Although there is experience with doses up to 30 mg/m2/week in pediatric patients, doses greater than 20 mg/m2/week may result in a significant increase in the incidence and severity of serious toxic reactions, especially bone marrow suppression. Doses between 20 and 30 mg/m2/week (0.65 to 1 mg/kg/week) may have better absorption and fewer gastrointestinal side effects if methotrexate is administered by an alternative route using another formulation. 

Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more. 

Certain side effects such as mouth sores may be reduced by folate supplementation with methotrexate in pJIA.
A process for the encapsulation of liquid particles within nanometer thick polymer shells utilizes an interfacial free radical alternating copolymerization process. Encapsulating a liquid material includes providing a mixture comprising the liquid material to be encapsulated, a hydrophobic monomer in a non-polar solution and a hydrophilic monomer in a polar solution. The liquid material is compatible in either the polar solution or the non-polar solution. The polar solution and the non-polar solution are not miscible in each other. The mixture is homogenized to form an emulsion, and then polymerized by an initiator which initiates an interfacial free radical alternating copolymerization process. The copolymerization process is optimally constrained to proceed only at the hydrophobic and hydrophilic interface thus forming a polymer around the liquid material.